# Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis

> **NCT00062699** · PHASE4 · TERMINATED · sponsor: **Abbott** · enrollment: 2200 (—)

## Conditions studied

- End-Stage Kidney Disease

## Interventions

- **DRUG:** Zemplar (paricalcitol injection)
- **DRUG:** Calcijex

## Key facts

- **NCT ID:** NCT00062699
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-04
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 2200 (—)
- **Last updated:** 2006-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00062699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00062699, "Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00062699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*